
Merck’s oncology programme has suffered a setback as a Phase III trial of its investigational integrin inhibitor cilengitide failed in …
Merck KGaA has completed patient enrollment for a phase III global trial of its first-in-class integrin inhibitor in a rare …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

